Email this article Sunitinib efficacy in patients with disseminated renal cell carcinoma
- Authors: Karyakin O.B.1, Popov A.M.1
-
Affiliations:
- Public institution, medical radiological research center, Russian Academy of Medical Sciences
- Issue: Vol 4, No 1 (2008)
- Pages: 25-28
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER
- Published: 30.03.2008
- URL: https://oncourology.abvpress.ru/oncur/article/view/1033
- DOI: https://doi.org/10.17650/1726-9776-2008-4-1-25-28
- ID: 1033
Cite item
Full Text
Abstract
Renal cell carcinoma belongs to a category of chemoresistant tumors. An overall life span of the patients with the disseminated form of disease amounts 10—12 months. Molecular biology development has brought to appearance of the novel kind of systemic treatment — «target» therapy. Use of the given group drugs allows improving the efficacy of the treatment of disseminated renal cancer. According to the guidelines of the European association of urology (EAU), sunitinib is approved as the first line therapy in patients with the favorable and doubtful prognosis.
About the authors
O. B. Karyakin
Public institution, medical radiological research center, Russian Academy of Medical Sciences
Author for correspondence.
Obninsk Russian Federation
A. M. Popov
Public institution, medical radiological research center, Russian Academy of Medical SciencesObninsk Russian Federation
References
Supplementary files
